Kerendia (finerenone) is indicated to reduce the risk of sustained decline in kidney function, kidney failure, cardiovascular death, non-fatal heart attack, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1][2].
What is Kerendia's mechanism of action?
Kerendia is a non-steroidal, selective mineralocorticoid receptor antagonist. By blocking the effects of excessive mineralocorticoid receptor stimulation, it helps to reduce inflammation and fibrosis in the kidneys and cardiovascular system [1][3].
How does Kerendia compare to other CKD treatments for type 2 diabetes?
Kerendia offers a distinct approach by targeting the mineralocorticoid receptor pathway, which plays a role in CKD progression and cardiovascular complications in patients with type 2 diabetes. This is different from treatments that primarily focus on glycemic control or blood pressure management [1][3].
What are the potential risks or side effects of taking Kerendia?
The most common side effects of Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. Patients should have their potassium levels monitored regularly, especially when starting Kerendia or changing doses [1][4].
When was Kerendia approved and by which regulatory bodies?
Kerendia received approval from the U.S. Food and Drug Administration (FDA) in July 2021 for its specified indication [2]. It has also been approved in other regions, including the European Union [3].
How is Kerendia supplied and what is the typical dosage?
Kerendia is available as oral tablets in various strengths. The starting dose is typically 10 mg once daily, which can be increased to 20 mg once daily based on tolerability and potassium levels [1][4].
Are there any specific patient groups for whom Kerendia is not recommended?
Kerendia is contraindicated in patients with hypersensitivity to finerenone or any of its excipients [1]. It is also not recommended for patients with certain adrenal conditions [1].
What are the key clinical trials supporting Kerendia's efficacy?
The efficacy of Kerendia was demonstrated in clinical trials such as the FIDELIO-DKD and FIGARO-DKD studies, which showed significant reductions in the risk of kidney and cardiovascular outcomes in patients with CKD and type 2 diabetes [1][3].
Where can I find more information on Kerendia's drug patents and exclusivity?
Information regarding Kerendia's patent status and exclusivity periods can be found on specialized databases like DrugPatentWatch.com [5].
What is the typical cost or insurance coverage for Kerendia?
Pricing and insurance coverage for Kerendia can vary. Patients often explore patient assistance programs or inquire about their specific insurance plans for detailed cost information [4].
What are the next steps for Kerendia in terms of research or potential new indications?
Ongoing research may explore Kerendia's effects in broader patient populations or for other related conditions. The clinical trial data has established its role in managing CKD and cardiovascular risk in patients with type 2 diabetes [3].
---
Sources:
1. https://www.kerendia.com/
2. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
3. https://www.bayer.com/en/newsroom/press-releases/2021/kerendia-finenone-approved-in-the-us-for-treatment-of-patients-with-chronic-kidney-disease-ckd-associated-with-type-2-diabetes-t2d-07132021
4. https://www.kerendia.com/patient-support
5. https://drugpatentwatch.com/